OPEN

SUBJECT AREAS:

PARASITE GENOMICS

GENETICS RESEARCH

MALARIA

TRANSLATIONAL RESEARCH

Genome-wide screen identifies new candidate genes associated with artemisinin susceptibility in *Plasmodium falciparum* in Kenya

Steffen Borrmann^{1,2}, Judith Straimer^{2,3*}, Leah Mwai^{1,7*}, Abdirahman Abdi¹, Anja Rippert², John Okombo¹, Steven Muriithi¹, Philip Sasi¹, Moses Mosobo Kortok¹, Brett Lowe¹, Susana Campino⁴, Samuel Assefa⁴, Sarah Auburn⁴, Magnus Manske⁴, Gareth Maslen⁴, Norbert Peshu¹, Dominic P. Kwiatkowski^{4,5}, Kevin Marsh^{1,6}, Alexis Nzila⁷ & Taane G. Clark⁸

Received
8 July 2013

Accepted
21 October 2013

Published
25 November 2013

Correspondence and requests for materials should be addressed to S.B. (sborrmann@kilifi.kemri-wellcome.org) or T.G.C. (taane.clark@lshtm.ac.uk)

* These authors contributed equally to this work.

¹KEMRI–Wellcome Trust Research Programme, Kilifi, Kenya, ²Institute of Microbiology, Magdeburg University School of Medicine, Germany, ³Dept. of Microbiology and Immunology, Columbia University, New York, NY, ⁴Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK, ⁵Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford, UK, ⁶Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK, ⁷Department of Chemistry, King Fahd University of Petroleum and Minerals, Dharan, Kingdom of Saudi Arabia, ⁸Faculties of Epidemiology and Population Health and Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London, UK.

Early identification of causal genetic variants underlying antimalarial drug resistance could provide robust epidemiological tools for timely public health interventions. Using a novel natural genetics strategy for mapping novel candidate genes we analyzed >75,000 high quality single nucleotide polymorphisms selected from high-resolution whole-genome sequencing data in 27 isolates of *Plasmodium falciparum*. We identified genetic variants associated with susceptibility to dihydroartemisinin that implicate one region on chromosome 13, a candidate gene on chromosome 1 (*PFA0220w*, a *UBP1* ortholog) and others (*PFB0560w*, *PFB0630c*, *PFF0445w*) with putative roles in protein homeostasis and stress response. There was a strong signal for positive selection on *PFA0220w*, but not the other candidate loci. Our results demonstrate the power of full-genome sequencing-based association studies for uncovering candidate genes that determine parasite sensitivity to artemisinins. Our study provides a unique reference for the interpretation of results from resistant infections.

Antimalarial drug resistance has repeatedly frustrated global efforts to limit morbidity and prevent mortality from *Plasmodium falciparum* malaria. Recently, landmark studies conducted in Western Cambodia in patients who had been treated with artemisinin derivatives have reported an alarming delay in parasite clearance^{1,2}. Since then, infections with increasingly delayed clearance were also reported from Western Thailand and it was suggested that this *in vivo* phenotype is genetically determined³. Because artemisinin-based combination chemotherapies are the backbone of global malaria control programs, this situation constitutes a public health emergency. Historically, Southeast Asia has been the origin of global spread of drug resistance-conferring mutations. The reason for this geographical bias is only partially understood, but ecological, behavioral and biological factors that may play a role include high rates of inbreeding in the mosquito vector, which reduce competition and favor clonal expansion of emerging genetic variants under drug pressure⁴, indiscriminate use of poor-quality drugs⁵ and possibly, “hyper-mutant” parasite strains⁶.

High throughput whole-genome sequencing technology has revolutionized the approach for identifying genetic variants associated with phenotypes of interest in natural populations. We have harnessed this natural genetic strategy for identifying novel candidate genes that modify the susceptibility of *P. falciparum* to antimalarial drugs. We hypothesized that the range of phenotypic variation observed in natural populations of *P. falciparum* is hard-wired to naturally occurring genetic variants, termed ‘standing variation’, without necessarily reflecting “resistance” as an evolutionary adaptation to selective pressure^{7,8}. Here we present the results of a genome-wide study in 27 isolates of *Plasmodium falciparum* obtained from malaria patients in Kilifi, Kenya.

Results

In vitro phenotyping of *P. falciparum* isolates from Kenyan malaria patients. Fully culture adapted *P. falciparum* isolates obtained from pediatric patients enrolled in a clinical trial in Kilifi District, Kenya⁹ were subjected to independently repeated growth inhibition assays to obtain reproducible drug sensitivity phenotypes (expressed as half-maximal inhibitory concentration; IC_{50}). We focused on a panel of 8 common antimalarial drugs based on their importance as former (chloroquine, CQ; pyrimethamine, PM; and desethyl-amodiaquine, DEAQ) and current (dihydroartemisinin, DHA; lumefantrine, LM; piperazine, PPQ; and quinine, QN) first or second line antimalarial treatments in Kenya. Mefloquine (MQ) was added because of its global importance for treating and preventing malaria. The median IC_{50} values (range) were 37 nM (12–310) for CQ; 22 μ M (3–70) for PM; 22 nM (7–120) for DEAQ; 2 nM (0.5–4) for DHA; 17 nM (4–85) for LM; 49 nM (24–122) for PPQ; 60 nM (12–140) for QN; and 29 nM (7–99) for MQ. The intra-sample correlation between IC_{50} assay replicates (a measure of reproducibility) was high (median: 0.97, range: 0.90–0.99). The median correlation between drug assays was 0.18, and varied between 0.01 (lumefantrine and quinine) and 0.76 (LM and MQ) (see Figure 1 for a summary of the assays). The observed pattern of correlations (Fig. 1) was consistent with previously published data (e.g., DHA and LM, 0.46 and DHA and MQ, 0.58)^{10,11}. We did not classify isolates into sensitive and resistant categories for several reasons. First, there is no general consensus on *in vitro* cutoff values and their relevance for *in vivo* resistance can be obscured by unrelated parameters (primarily, of pharmacokinetic and immunological nature). For the artemisinin class of drugs, only recently studies started to address the relationship between specialized novel *in vitro* assays (not done here) and the delayed parasite clearance phenotype observed *in vivo*¹². Secondly, there is increased statistical power in using quantitative, as opposed to qualitative, data for association analyses.

Whole genome sequence analysis. The sequencing technology yielded a median of 18.7 (range: 8.6–38.8) million 54–76 base-pair

reads across the 27 samples. Mapping uniquely the reads to the reference 3D7 genome¹³ yielded a genome-wide average of 57.3-fold coverage, and a median of 86.2% of the genome being covered, 69.6% to at least a five-fold coverage level. The average number of allelic differences to 3D7 (at an error rate of 1 per 1000) was 8899/strain, and across all samples 182,357 positions were identified, leading to 75,471 high quality bi-allelic SNPs (with <10% missing alleles per position among all samples, minor allele frequency of 5%) carried forward for further analysis. The vast majority of SNPs (66,966, 88.7%) contained no heterozygous genotype calls. Overall, only 0.6% of genotype calls were heterozygous, potentially indicative that few infections/isolates were multi-clonal. Using a principal component analysis on the SNPs, there was no evidence of any samples being continental outliers or identical genetically (for instance, due to potential contamination) (Fig. S1).

Association analysis. Because of the observed deviation from a normal distribution of *in vitro* responses (Fig. 1) we applied a conservative non-parametric tests for the phenotype-genotype association analysis (Table 1, Table S1). We observed ten-fold differences in the range of IC_{50} values (the ‘effect size’) for chloroquine and DHA (Figure 1), with standard deviations of measurements of at most 30% of values¹⁴. With a sample size of 27, we would expect to have over 95% power (5% type I error) to detect a 3-fold difference using a Wilcoxon test at a minimum allele frequency of 7.4% (2/27). Similarly, we are able to detect a two-fold difference at a minimum allele frequency of 11.1% (3/27).

In a first analysis, we sought to internally validate our approach by using chloroquine resistance as reference. Indeed, we identified *MAL7P1.27*, which encodes the chloroquine resistance transporter (CRT), as the most significant association hit covered by four coding SNPs ($P \leq 10^{-4}$) on chromosome 7 (Table S1, Fig. S1).

Based on these reassuring results, we instituted a screen for associations with susceptibilities to 8 drugs. The following number of SNPs (genes, intergenic positions not listed) were lower than the computed significance threshold of 7×10^{-4} (Table 1): (i) 2 hits for PPQ (*PF07_0019*), (ii) 1 hit for LM (0), 5 hits for DHA

Figure 1 | Half-maximal inhibitory concentrations (IC_{50}) for drug assays (phenotypes). The diagonal is a histogram of the phenotypes, right diagonal is the Spearman's correlation between assays; left diagonal is raw data and smoothed relationship using cubic splines; DHA dihydroartemisinin, LM lumefantrine, PPQ piperazine, CQ chloroquine, PM pyrimethamine, MQ mefloquine, QN quinine, DEAQ desethylamodiaquine.

Table 1 | Association hits*

Drug	Chr	Position	Gene	Non-ref AF	P-value
PPQ	MAL2	846411	-	0.400	0.000175
PPQ	MAL7	294258	PF07_0019	0.727	0.000467
LM	MAL12	58573	-	0.591	0.000555
DHA	MAL1	195090	PFA0220w	0.182	0.000273
DHA	MAL13	717855	-	0.300	0.000052
DHA	MAL2	514461	PFB0560w	0.227	0.000152
DHA	MAL2	564143	PFB0630c	0.706	0.000323
DHA	MAL6	377293	PFF0445w	0.682	0.000528
CQ	MAL1	535243	PFA0665w	0.300	0.000361
CQ	MAL11	466177	PF11_0127	0.714	0.000258
CQ	MAL11	1984983	-	0.810	0.000334
CQ	MAL12	58558	-	0.421	0.000185
CQ	MAL12	58573	-	0.591	0.000555
CQ	MAL12	1952993	PFL2270w	0.227	0.000532
CQ	MAL12	1958385	-	0.200	0.000413
CQ	MAL14	1724141	-	0.421	0.000027
CQ	MAL3	638508	PFC0690c	0.182	0.000547
CQ	MAL6	408695	PFF0475w	0.773	0.000304
CQ	MAL7	446872	-	0.545	0.000300
CQ	MAL7	447960	-	0.737	0.000172
CQ	MAL7	459785	MAL7P1.27	0.524	0.000108
CQ	MAL7	460214	MAL7P1.27	0.500	0.000054
CQ	MAL7	461216	MAL7P1.27	0.500	0.000054
CQ	MAL7	461609	MAL7P1.27	0.524	0.000108
CQ	MAL7	462908	-	0.500	0.000288
CQ	MAL7	952716	MAL7P1.108	0.682	0.000352
CQ	MAL9	705210	-	0.350	0.000310
CQ	MAL9	1280862	PFI1560c	0.682	0.000352
CQ	MAL9	1280868	PFI1560c	0.682	0.000352
QN	MAL12	158431	PFL0135w	0.682	0.000528
QN	MAL13	103008	PF13_0075	0.318	0.000352
QN	MAL13	103215	PF13_0075	0.318	0.000352
QN	MAL13	1466682	PF13_0201	0.364	0.000281
QN	MAL13	2636505	MAL13P1.333	0.182	0.000273
QN	MAL14	908234	PF14_0215	0.667	0.000431
QN	MAL14	2773249	PF14_0647	0.545	0.000300
QN	MAL14	3121047	PF14_0726	0.550	0.000536
QN	MAL2	70533	-	0.250	0.000258
QN	MAL2	70541	-	0.250	0.000258
QN	MAL2	70752	-	0.250	0.000258
QN	MAL2	70779	-	0.250	0.000258
QN	MAL2	70796	-	0.250	0.000258
QN	MAL4	663941	PFD0700c	0.250	0.000258
QN	MAL6	1287339	-	0.524	0.000380
QN	MAL7	574869	-	0.368	0.000159
PM	MAL1	177518	-	0.333	0.000120
PM	MAL1	442138	PFA0555c	0.286	0.000442
PM	MAL1	514844	PFA0650w	0.591	0.000004
PM	MAL1	515098	PFA0650w	0.273	0.000188
PM	MAL10	1438690	PF10_0356	0.636	0.000281
PM	MAL11	1020735	PF11_0271	0.636	0.000044
PM	MAL11	1263782	PF11_0334	0.773	0.000152
PM	MAL14	2169608	-	0.250	0.000516
PM	MAL14	3174785	-	0.611	0.000440
PM	MAL2	376222	PFB0405w	0.364	0.000119
PM	MAL3	651126	PFC0705c	0.591	0.000390
PM	MAL3	773402	PFC0820w	0.444	0.000548
PM	MAL3	921578	PFC0970w	0.727	0.000509
PM	MAL4	1134664	-	0.227	0.000532
PM	MAL4	1134707	-	0.227	0.000532
PM	MAL6	575552	PFF0670w	0.318	0.000082
PM	MAL7	1150591	PF07_0107	0.524	0.000170
PM	MAL8	1312984	PF08_0002	0.455	0.000300
DEAQ	MAL1	94893	-	0.333	0.000431
DEAQ	MAL1	132613	PFA0150c	0.263	0.000172
DEAQ	MAL1	403297	PFA0510w	0.182	0.000273
DEAQ	MAL11	972835	-	0.545	0.000300
DEAQ	MAL11	1228186	PF11_0327	0.273	0.000322
DEAQ	MAL11	1476544	PF11_0388	0.190	0.000334

Table 1 | Continued

Drug	Chr	Position	Gene	Non-ref AF	P-value
DEAQ	MAL13	786385	PF13_0104	0.714	0.000442
DEAQ	MAL13	1942726	PF13_0254	0.227	0.000152
DEAQ	MAL2	849778	-	0.545	0.000207
DEAQ	MAL2	849818	-	0.545	0.000207
DEAQ	MAL2	849823	-	0.545	0.000207
DEAQ	MAL2	849837	-	0.545	0.000207
DEAQ	MAL2	849896	-	0.545	0.000207
DEAQ	MAL3	448562	-	0.182	0.000273
DEAQ	MAL4	1136713	-	0.211	0.000516
DEAQ	MAL7	254907	PF07_0016	0.227	0.000152
DEAQ	MAL7	254910	PF07_0016	0.227	0.000152
DEAQ	MAL8	116107	MAL8P1.157	0.318	0.000352
DEAQ	MAL8	311608	-	0.211	0.000516
DEAQ	MAL8	452012	PF08_0105	0.286	0.000442
MQ	MAL5	1119259	PFE1330c	0.818	0.000547

*Wilcoxon non-parametric tests with $P < 0.006$ are presented; DHA dihydroartemisinin, LM lumefantrine, PPQ piperaquine, CQ chloroquine, PM pyrimethamine, MQ mefloquine, QN quinine, DEAQ desethylamodiaquine.

(PFA0220w, PFB0560w, PFA0630c, PFF1445w), (iii) 21 hits for CQ 21 (MAL7P1.108 MAL7P1.27, PF11_0127, PFA0665w, PFC0690c, PFF0475w, PFI1560c, PFL2270w), (iv) 14 hits for QN (MAL13P1.333, PF13_02¹⁵01 PF14_0215, PF14_0647, PF14_0726, PFD0700c, PFL0135w), (v) 1 hit for MQ (PFE1330c), (vi) 17 hits for PM (PF07_0107, PF10_0356, PF11_0271, PF11_0334, PFA0555c, PFA06-50w, PFB0405w, PFC0705c, PFC0820w, PFC0970w, PFF0670w) and (vii) 19 for DEAQ (MAL8P1.157, PF07_0016, PF11_0327, PF11_0388, PF13_0104, PF13_0254, PFA0150c, PFA0510w). These hits were confirmed using the Spearman's rank approach (Table S1). Of particular interest were two SNPs associated with DHA susceptibility on chromosome 13 at nucleotide positions 717855 and 1644675 (Wilcoxon, $P = 5 \times 10^{-5}$; Spearman's rank, $P = 5 \times 10^{-5}$; Tables 1, S1) that represented the most significant hits across all comparisons. Equally of major interest was a coding SNP (C->G; K873R) in PFA0220w that was found to be associated with DHA sensitivity. A homolog of this gene was originally identified in *P. chabaudi* as determinant of parasite survival in artemisinin drug treated murine hosts (PCHAS_020720, encoding a putative deubiquitinase)¹⁵. Another SNP associated with DHA response implicated PFB0630c, a gene that has homology to stress-responsive RNA polymerase II-binding proteins¹⁶. There was some evidence for SNP associations in other candidate regions for the other tested drugs, including DHFR (PM, PFD0830w, $P = 0.0173$), MDR1 (MQ, PFE1150w, $P = 0.0038$), MRP2 (QN, PFL1410c, $P = 0.0052$), NHE-1 (QN, PF13_0019, $P = 0.0033$), but these did not exceed the stringent significance threshold (Table S2). Among the collected samples we did not find evidence of the MDR1 gene (PFE1150w) amplification, which had been found to be associated with MQ resistance¹⁷. Because it has recently been suggested that only a very limited number of genes may be involved in modifying drug susceptibility¹⁸, we studied the specificity of SNP hits for a given drug by querying the database for significant association with other drugs (Table S2). Not a single SNP hit was associated with more than one drug when using a moderate significance threshold for secondary associations (Table S2). There was a single hit for lumefantrine (MAL7P1.30) that occurred in a region highlighted by several hits for CQ on chromosome 7 (Table S2). The top 0.05% correlations (corresponding to either, $\rho > 0.68$ or $p < 0.0007$) were retained from Table S1.

Signatures of recent positive selection. Drug pressure is a powerful selective force in natural *Plasmodium* populations^{19,20}. It is well understood that positive selection acting on a beneficial trait gives rise to characteristic regions of low genetic diversity surrounding the

causal genetic variant(s) due to the preservation of linkage disequilibrium during meiosis (recombination in regions of 17 kb is estimated to occur only in 1% of meioses during this life-cycle bottleneck in the mosquito mid-gut²¹). Here, we sought to identify regions of the genome under recent positive selection, as these may represent signatures of adaptation to drug pressure (Table 2, Figure 3). To achieve this, we calculated the integrated haplotype score (iHS) for all 75 k SNPs across the whole genome, applying a stringent threshold ($iHS > 3.6$, top 0.2%). Again in an initial validation of the analytical approach using the established chloroquine resistance locus *CRT* as positive control, we found a large 45 kb region surrounding *CRT* that was characterized by lower than expected genetic diversity (PF07_0028 (2), PF07_0035 (6), PF07_0036 (1), PF07_0037 (1), MAL7P1.30 (1), and PF07_0042 (2)).

We identified the following genes located in such 'valleys' of low diversity (number of SNP hits) in the genome-wide scan: (i) PFA-0205w (2), (ii) PFA0220w (UBP1-homologue) (1), (iii) PFC0935c (2) (coding for a putative N-acetylglucosamine-1-phosphate transferase), (iv) PFC0940c (1), (v) PFE1210c (1), (vi) PFF1350c (13) (coding for a putative member of the acetyl-CoA synthetase family²²), (vii) PFF1365c (2), (viii) PFF1485w (1), (ix) PF07_0004 (3), (x) MAL7P1.207 (2), (xi) PF07_0066, (xii) a 50 kb region downstream of PFDHPS (MAL8P1.112 (1), MAL8P1.113 (5), PF08_0100 (1), (xiii) PFI0805w (1), (xiv) PF10_0015 (2), (xv) PF11_0074, (xvi) PF11_0420 (2), (xvii) PFL1525c (1), (xviii) PFL1835w (1), (xix) PF14_0726 (3).

The |iHS| method may be insensitive to detect signatures of positive selection for polymorphisms that have reached fixation, we therefore proceeded to apply the cross-population extended haplotype score (XP-EHH) approach to compare the Kenyan to other *P. falciparum* populations (Burkina Faso, Cambodia, Mali, Thailand) to identify evidence for positive selection of alleles that have reached or are near fixation in individual populations²³. The analysis confirms selection acting on PfdCRT across all comparisons, but also at the PfdHPS locus across African populations (Fig. S2).

In our analysis of genomic regions with low diversity, we also found the current vaccine candidates MSP1 (2), AMA1 (4) (previously described by Mu et al.²⁴), and TRAP (6). This was a surprising finding because these genes are thought to be targets of protective immunity and are known to contain extensive SNP and/or repeat polymorphisms. To obtain reassurance that our finding did not result from spurious genomic data, we implemented the Tajima's D metric²⁵, an approach for distinguishing between a DNA sequence evolving randomly ("neutrally", values close to zero) and one evolving under a non-random process, including directional selection (low negative values) or balancing selection (high positive values).

Table 2 | Signatures of recent positive selection*

Chromosome	Position	frequency	Allele	Gene	iHS
MAL1	180291	0.130	A	PFA0205w	3.941
MAL1	180421	0.717	A	PFA0205w	5.118
MAL1	192889	0.217	G	PFA0220w	3.652
MAL2	839683	0.152	A	PFB0935w	3.669
MAL3	137202	0.870	A	PFC0120w	4.850
MAL3	884959	0.109	A	PFC0935c	4.843
MAL3	884962	0.109	A	PFC0935c	4.844
MAL4	545613	0.109	G	PFD0595w	3.611
MAL4	611365	0.717	G	-	3.810
MAL4	805223	0.065	G	PFD0872w	3.763
MAL4	994422	0.065	C	PFD1030c	3.982
MAL4	1148234	0.630	A	PFD1215w	3.958
MAL4	1148261	0.522	A	PFD1215w	3.692
MAL5	929750	0.457	G	PFE1120w	3.621
MAL5	1011110	0.391	C	PFE1210c	3.799
MAL6	1030822	0.304	G	PFF1225c	3.677
MAL6	1114493	0.500	A	-	4.840
MAL6	1114518	0.543	A	-	4.154
MAL6	1114565	0.565	G	PFF1350c	3.973
MAL6	1114588	0.543	A	PFF1350c	4.201
MAL6	1114626	0.543	A	PFF1350c	4.201
MAL6	1114909	0.543	C	PFF1350c	4.201
MAL6	1114929	0.543	A	PFF1350c	4.201
MAL6	1114952	0.543	C	PFF1350c	4.201
MAL6	1115373	0.565	G	PFF1350c	4.846
MAL6	1115454	0.587	A	PFF1350c	4.802
MAL6	1116047	0.609	T	PFF1350c	4.853
MAL6	1116102	0.587	T	PFF1350c	4.786
MAL6	1116171	0.609	A	PFF1350c	4.730
MAL6	1116315	0.587	T	PFF1350c	4.821
MAL6	1117520	0.609	A	PFF1350c	3.786
MAL6	1128749	0.543	G	PFF1365c	4.064
MAL6	1132351	0.500	G	PFF1365c	3.959
MAL6	1268976	0.348	C	PFF1470c	4.036
MAL6	1271588	0.217	T	-	4.432
MAL6	1282898	0.196	T	PFF1485w	4.929
MAL6	1283740	0.087	T	-	4.064
MAL7	430849	0.391	T	PF07_0028	3.763
MAL7	431906	0.326	C	PF07_0028	3.860
MAL7	465618	0.870	C	PF07_0035	3.716
MAL7	465787	0.478	C	PF07_0035	6.267
MAL7	465791	0.543	A	PF07_0035	4.825
MAL7	465810	0.587	T	PF07_0035	4.109
MAL7	466389	0.261	T	PF07_0035	3.963
MAL7	466988	0.457	T	PF07_0035	4.196
MAL7	467844	0.370	A	PF07_0036	4.568
MAL7	476798	0.370	G	PF07_0037	3.732
MAL7	503466	0.717	G	MAL7P1.30	3.850
MAL7	520886	0.109	A	PF07_0042	3.626
MAL7	524323	0.065	T	PF07_0042	4.668
MAL7	665933	0.152	C	-	3.713
MAL7	761532	0.087	G	PF07_0066	4.206
MAL7	1440395	0.370	C	-	4.991
MAL8	469790	0.304	T	PF08_0102	3.840
MAL8	479954	0.174	C	-	3.632
MAL8	491667	0.239	A	MAL8P1.113	5.274
MAL8	491757	0.217	C	MAL8P1.113	5.665
MAL8	491831	0.217	G	MAL8P1.113	5.853
MAL8	491883	0.217	C	MAL8P1.113	5.856
MAL8	492065	0.587	T	MAL8P1.113	4.366
MAL8	502511	0.304	A	PF08_0100	4.319
MAL8	506087	0.283	T	MAL8P1.112	4.061
MAL9	599641	0.087	G	PFI0685w	3.867
MAL9	689167	0.891	A	PFI0805w	4.711
MAL9	1202400	0.065	T	PFI1475w	3.920
MAL9	1202416	0.065	A	PFI1475w	3.920
MAL9	1202437	0.065	T	PFI1475w	3.920
MAL9	1202504	0.065	C	PFI1475w	3.921
MAL10	61593	0.304	A	-	4.516

Table 2 | Continued

Chromosome	Position	frequency	Allele	Gene	iHS
MAL10	68880	0.065	C	PF10_0015	3.600
MAL10	68888	0.065	A	PF10_0015	3.660
MAL10	879301	0.065	G	PF10_0211	3.873
MAL10	1524131	0.522	A	PF10_0374	3.784
MAL10	1524172	0.370	T	PF10_0374	3.862
MAL10	1543093	0.478	A	PF10_0374	4.313
MAL11	265298	0.065	T	PF11_0074	4.526
MAL11	681352	0.717	G	PF11_0185	4.136
MAL11	681360	0.739	G	PF11_0185	4.185
MAL11	1294582	0.261	A	PF11_0344	6.442
MAL11	1294701	0.348	C	PF11_0344	4.887
MAL11	1294706	0.217	C	PF11_0344	6.074
MAL11	1294751	0.370	A	PF11_0344	4.403
MAL11	1637771	0.087	T	PF11_0420	3.604
MAL12	57132	0.109	G	-	5.100
MAL12	57138	0.152	T	-	4.183
MAL12	95229	0.152	A	PFL0070c	3.764
MAL12	1579059	0.196	G	PFL1835w	4.093
MAL13	1465418	0.152	C	PF13_0201	4.118
MAL13	1465808	0.130	C	PF13_0201	3.624
MAL13	1465878	0.478	C	PF13_0201	4.519
MAL13	1465929	0.543	C	PF13_0201	4.213
MAL13	1465950	0.478	G	PF13_0201	3.931
MAL13	1466282	0.804	C	PF13_0201	3.900
MAL13	1466322	0.370	C	PF13_0201	4.446
MAL13	1466429	0.913	T	PF13_0201	4.973
MAL13	1466471	0.283	A	PF13_0201	3.921
MAL14	542167	0.087	A	PF14_0135	4.274
MAL14	1986848	0.891	T	PF14_0463	3.759
MAL14	1986850	0.913	T	PF14_0463	3.984
MAL14	3121318	0.348	T	PF14_0726	3.625
MAL14	3121371	0.261	C	-	4.836
MAL14	3121449	0.174	G	PF14_0726	5.866

*using the integrated haplotype score (iHS, absolute values >3.6 are presented).

Indeed when calculating the Tajima's D on a gene-by-gene basis we found 18 loci, including *AMA1*, *MSP3*, *MSP3.8*, *MSP6* vaccine candidates (Table S3). These results could indicate the co-existence of reverse selective forces on different domains and/or upstream and downstream regulatory elements of the same gene. For instance, purifying selection could act on functional domains such as trans-membrane stretches or functional motives while at the same time, diversifying selection acts on immunologically exposed extracellular loops²⁶. Alternatively, the co-existence of hyper-variable 'islands' within regions of lower than expected diversity may point to a previously unrecognized feature of chromosome biology that is providing a pathway for diversification at amino acid residues or entire domains exposed to adaptive immune responses.

Association and selection by gene. Recent positive selection of survival-promoting genotypes, such as drug resistance-conferring mutations, should be detectable both by genotype-phenotype association and by 'phenotype-free' analysis of genomic structures (see above section on signatures of recent positive selection) as long as (i) selective pressure has had sufficient time to shape evolution or on the opposite end of the evolutionary time scale, (i) the causal genetic variant has not yet reached fixation in the population (i.e., close to 100% prevalence). We used a simple composite score (termed 'total evidence score', TES) calculated as the sum of the negative decadic logarithm ($-\log_{10}$) of the P-value for association and the iHS score for unusually large haplotypes for each of the 75,471 high-quality bi-allelic SNPs (Figure 4 and Table S4). Among the top twenty highest ranked SNPs, we found *CRT* (MAL7P1.27), *Cg1* (immediately downstream of *CRT*), and *UBP1*. Of the 44 genes (1.7% of 2591 passing QC) identified by selection or

Figure 2 | Manhattan plots of whole genome association tests. X-axis is Chromosomes 1 to 14 in alternating colors; Y-axis is the $-\log_{10}$ p-value from a Wilcoxon test; points in blue indicate P-values less than 0.0007 (above horizontal dashed line); DHA *dihydroartemisinin* (Fig. 2A), LM *lumefantrine* (Fig. 2B), PPQ *piperaquine* (Fig. 2C), CQ *chloroquine* (Fig. 2D), PM *pyrimethamine* (Fig. 2E), MQ *mefloquine* (Fig. 2F), QN *quinine* (Fig. 2G), DEAQ *desethylamodiaquine* (Fig. 2H).

association (Table S4), only *UBP1*, *CRT* and surrounding loci (PF07_0035), and *PF14_0726* gene regions were identified by both approaches, providing stronger evidence for their role in modulating drug sensitivity. The biological relevance of a modest correlation between association P-values and selection tests (Spearman's correlation 0.41) at a gene level in entire *P. falciparum* genomes is not clear and it may be an artifact stemming from limits to attain significance with low frequency variants in both tests (Fig. 4).

The collected samples were all resistant to pyrimethamine, and there is some evidence of a selective sweeps within 50 kb of the *DHFR* gene and in the 3' region of *DHPS* (which encodes the target of sulfadoxine, involved in the combination therapy with

pyrimethamine). The iHS metric is powered to detect sweeps only at intermediate frequency and prior to fixation. This could explain the failure to detect a stronger signal in our samples, all of which were resistant to pyrimethamine *in vitro* and carried the resistance-conferring gatekeeper mutation at codon position 108 (S108N).

Discussion

The identification of loci associated with malarial drug resistance has the potential to support disease surveillance systems and provide public health bodies with the information needed to deliver effective interventions. Here we studied associations between (i)

Figure 3 | Evidence of recent positive selection. We used the integrated Haplotype Score (iHS), where points above the horizontal dashed line indicated scores in excess of 3.6; x-axis is Chromosomes 1 to 14 in alternating colors; vertical lines correspond to chromosomal locations of *DHFR*, *MDRI*, and *CRT*, *DHPS*, respectively (left to right). Larger sized points indicate significant results in unique, non-telomeric and non-highly variable gene regions.

whole-genome sequence variation at single-nucleotide resolution obtained through next-generation sequencing technology and (ii) robust drug susceptibility phenotypes obtained through repeat *in vitro* experiments with the aim to discover novel genes or genomic regions that modify drug susceptibility in 27 isolates of *P. falciparum* collected from Kenyan patients with malaria.

The power of our approach could be demonstrated in an initial proof-of-principle screen for chloroquine resistance-associated genes. The most significant association was found for the *CRT* gene that encodes the well-characterized chloroquine resistance transporter^{27,28}. When extending the analysis to seven important antimalarial drugs, including dihydroartemisinin as both active metabolite and component of the current front-line artemisinin-based combination therapies, we identified several additional loci that were strongly associated with drug response phenotypes (Table 1 and Fig. 2A–H). Because of the urgency of the artemisinin resistance problem^{1–3}, we focused on specific hits associated with the dihydroartemisinin response phenotype. We could confirm the previously reported association with *PFA0220w*, a homologue of *UBP1* previously identified in a rodent malaria model and coding for a putative de-ubiquitinating protein^{15,29}, and we identified three novel candidate genes (*PFB0560w*, *PFB0630c*, *PFF0445w*). Of note, our screen also identified a SNP (MAL13-1644675) located in a 35-kb segment on chromosome 13 that was recently linked to delayed *in vivo* clearance in *P. falciparum* infections from Western Thailand³⁰. *PFB0630c* shares homology with the human RPAP2 protein and the yeast Rtr1 protein¹⁶ with putative regulatory roles in RNA polymerase II function. This may be of interest in the light of the reported

differential expression pattern observed in isolates obtained from *P. falciparum* infections with delayed *in vivo* responses in Cambodia³¹. *PFB0560w* and *PFF0445w* are conserved *Plasmodium* protein coding genes with no assigned putative functions. *PFF0445w* had previously been reported to be up-regulated in response to artemisinin pressure *in vitro* in a comparative proteomics study³². The functional relevance of the chromosome 13 hit (MAL13-1644675; correlation $\rho = 0.7$; $P = 0.001$), centered between the predicted open reading frames MAL13P1.211 (−1 kb, coding for a hypothetical protein with no predicted function) and PF13_0226 (1.7 kp, predicted to code for an inner membrane complex (IMC) protein) is not known.

We also screened for evidence of recent positive selection in the genomes of our samples. Of particular interest was a strong signal surrounding *PFA0220w* (*UBP1*-homologue) (Fig. S1). However, we did not detect a similar selection signal for MAL13-1644675 in a 35-kb segment on chromosome 13 that was recently linked to delayed *in vivo* clearance in *P. falciparum* infections from Western Thailand³⁰. The fact that our screen identified an isolated association at this locus without a signal for recent positive selection may be explained by the evolutionary time point of sampling: artemisinin-based combination therapy was introduced as first-line treatment only 2–3 years before sampling started³³. This hypothesis is supported by evidence for the chloroquine resistance gene *CRT* where both association and signature of selection are present in our data, most likely as a result of longstanding drug pressure^{19,34}. The absence of significantly delayed *P. falciparum* infections in Kilifi after artemisinin treatment despite the moderate allele frequency of MAL13-1644675 in the local

Figure 4 | Scatter plot of evidence scores from genotype-phenotype association and genomic structure analyses. Values of iHS or $-\log_{10}$ P-value from association testing are presented, with the gene names that exceed thresholds (blue: iHS > 3.6 or $p < 0.0007$; red: iHS > 3 or $p < 0.001$). The Spearman's correlation is 0.417 ($P < 0.00001$).

parasite population suggests that this, or yet unknown causal, genetic variants in this region on chromosome 13 are required but not sufficient for full blown *in vivo* artemisinin tolerance. Of note, a genome-wide analysis for associations of genotypes with the rate of parasite clearance after treatment with artemisinin-based combinations in patients who donated the *P. falciparum* isolates for this study (presence or absence of microscopically detectable blood stage parasites on day 2⁹) did not reveal significant signals (Fig. S2).

In this study we used a panel of 8 commonly used antimalarial drugs to determine robust chemosensitivity phenotypes. This focus on *in vitro* data was motivated by a lack of correlation between the reported delayed *in vivo* response to artemisinins and the *in vitro* phenotype in most^{1,9}, if not all², studies. Whilst an *in vivo* phenotype would have been preferred, these phenotypes are difficult to measure, and the outcome can be confounded by host genetic, immunity and intra-assay variation. In contrast, the IC₅₀ values measured in 27 *P. falciparum* isolates obtained from pediatric patients in Kilifi District on the Kenyan Coast exhibited substantial phenotypic variation (mean >10-fold; Fig. 1) and a high degree of inter-assay reproducibility. The observed pattern of correlations between drug responses was also consistent with previously published data, reinforcing the confidence in the accuracy of the phenotypes.

In general, complex genetic traits may involve many genes, each of small effect magnitude. However, drug resistance in *P. falciparum* has been reported as strong single locus effects, with beneficial alleles rapidly going to fixation by selective sweeps leaving characteristic low-diversity 'scars' in the genomes of resistant

parasites. In practice, that translates into smaller sample size requirements for detecting selection events, compared to association studies for complex traits³⁵. To account for the potential number of false positives, we applied stringent quality control on the polymorphisms included, a conservative non-parametric testing and an adjusted statistical significance threshold. Our approach relied on natural variation in the parasite, leading to a set of strong candidates, including hitherto unexpected pathways. For instance, the associations of *TRAP* and of *PF14_0647* (coding for a putative Rab GTPase activator) with sensitivity to quinine (a known ion channel blocker³⁶) (Table 1) may point to a role of membrane-associated trafficking in the mechanism of action of quinine.

Our approach is conceptually similar to a study by Mu et al.²⁴ but with >20 times higher resolution of genetic variation, and with a focus on a single local parasite population obtained from patients in a well-described cohort^{9,37} to reduce potential confounding by population structure. In contrast to Mu et al.²⁴ we found one gene (*PFA0655w*) to be associated with chloroquine, and not mefloquine or dihydroartemisinin, sensitivity and we failed to find evidence for *MDR1*. Another study by van Tyne et al.³⁸ also reported on a genome-wide association study using an array-based genotyping strategy. There was partial overlap in the drugs used and specifically, we could not confirm a gene (*PF14_0654*) associated with artemisinin sensitivity, possibly related to a lack of power in our small sample size. A parallel study by Park et al.³⁹ could also confirm the efficiency of massively parallel shot-gun sequencing by employing a related strategy designed to increase the resolution of an initial positive

selection-based screen by using association test results³⁹. In contrast to Park et al., however, we did not assume selection through drug pressure to be driving allele frequencies conferring tolerance to the artemisinins relatively shortly after the introduction of artemisinin-based combination chemotherapies. Consequently, we used genomic signatures of positive selection not as a primary screen but as an additional parameter for identifying genes and/or genomic regions associated with artemisinin response rates through non-parametric genotype-phenotype association tests.

In summary, our study in a limited number of *P. falciparum* isolates has shown that a natural genetics approach powered by whole genome sequencing using new short read technologies can identify novel chemosensitivity-determining genes, applied particularly within a robust genome-wide association and selection setting. These results show promise for geographically focused and timely sequence-based studies as a powerful and efficient tool in future disease surveillance programs. We found substantial overlap with previously reported artemisinin resistance-associated candidate genes and regions (prominently, *PFA0220w*, a *UBP1*-homologue and a 35-kb segment on chromosome 13). Because the studied isolates did not originate from artemisinin resistant infections, we hypothesize that the observed associations indicate standing variation that could serve as substrate for selection under continued drug pressure. It also provides a unique reference for the interpretation of results from resistant infections.

Methods

In vitro phenotypes. The study was approved by the National KEMRI Ethical Review Committee, Kenya; the Oxford Tropical Research Ethics Committee, UK; and the Ethics Committee, Heidelberg University School of Medicine, Germany. Parasite isolates were obtained in 2007 to 2008 from patients presenting with uncomplicated episodes of *P. falciparum* malaria before initiation of treatment with an artemisinin-based combination therapy ($n = 13$) and when patients experienced recurrence of infection during follow-up ($n = 14$). Cryo-preserved isolates were consecutively thawed and adapted to cell culture conditions. Parasites were cultured in complete medium (RPMI supplemented with L-glutamine, 2% heat-inactivated AB serum, 0.1 mM hypoxanthine, gentamicin, and albumax II) in the presence of O+ or A+ blood at 5% packed cell volume and a gas mixture of 5% CO₂, 5% O₂ and 90% N₂. Growth inhibition of parasite cultures at 0.5% packed cell volume and 0.1% parasitemia was determined on 96-well plates by exposure to serial dilutions of dihydroartemisinin (DHA, Sigma), lumefantrine (LM, Novartis), piperazine (PPQ, SigmaTau), chloroquine (CQ, Sigma), pyrimethamine (PM, Sigma), mefloquine (MQ, Sigma), N-desethylamodiaquine (DEAQ, Sigma) and quinine (QN, Sigma). After incubation at 37°C for 72 hours, 20 nM SYBR green in lysis buffer (20 mM Tris at pH 7.5, 5 mM EDTA, 0.008% (wt/vol) saponin, and 0.08% (vol/vol) Triton X-100) (doi:10.1128/AAC.01607-06) was added and fluorescence intensity measured at 20 nm (model, manufacturer). Growth inhibition experiments were repeated at least twice (mean, 3.1). Half-maximal inhibitory concentrations (IC₅₀) were estimated by non-linear regression.

Sequencing and genetic variant analysis. All samples ($n = 27$) underwent whole genome sequencing, with 54 or 76-base paired end fragment sizes, using Illumina technology (see⁴⁰ for a description), and processed as previously described⁴¹ to identify variation including SNPs and small insertions and deletions. In brief, we mapped all isolates to the 3D7 (version 3.0) reference genome using *smalt* (5), and called variants using *samtools* (6). Sequence polymorphisms were identified empirically using sequence coverage data as previously described (4). The internal replicability and correlation between *in vitro* phenotypes was assessed using Spearman's correlation. Geographical outliers were identified using a principal component clustering approach applied to multi-continental SNP data (⁴⁰, Short read archive (SRA) Study ERP000190). The integrated haplotype score (iHS, (12)) method was applied to SNPs data to identify long-range directional selection. The selection metric Tajima's D²⁵ was used for distinguishing between a DNA sequence evolving randomly ("neutrally", values close to 0) and one evolving under a non-random process, including directional selection (low negative values) or balancing selection (high positive values). Because of the non-symmetry of phenotypes, the primary assessment of association between phenotypes and genetic variants (alleles) used Wilcoxon rank tests. A secondary analysis applied Spearman's correlation. A statistical significance cut-off ($P = 0.0007$, $-\log_{10} P = 3.15$) was inferred by simulation (phenotype-based permutation) to represent a multiple test adjustment of a nominal 5% error rate. For the final hits, we considered only genomic variants in regions that were unique (calculated by sliding 50 base pairs of contiguous sequence across the reference genome), non-subtelomeric, and not in highly variable gene families (*rifins*, *surfin*s, *stevors*, and *vars*). Regions for follow-up were compared to publically available sequence

data^{40,42}. All raw sequencing data for this work is contained in SRA study ERP000190.

1. Dondorp, A. M. *et al.* Artemisinin resistance in *Plasmodium falciparum* malaria. *N Engl J Med* **361**, 455–67 (2009).
2. Noedl, H. *et al.* Evidence of artemisinin-resistant malaria in western Cambodia. *N Engl J Med* **359**, 2619–20 (2008).
3. Phyo, A. P. *et al.* Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. *Lancet* (2012).
4. Eastman, R. T. & Fidock, D. A. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. *Nat Rev Microbiol* **7**, 864–74 (2009).
5. Nayyar, G., Breman, J., Newton, P. & Herrington, J. Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. *Lancet Infect Dis* **12**, 488–496 (2012).
6. Rathod, P. K., McErlean, T. & Lee, P. C. Variations in frequencies of drug resistance in *Plasmodium falciparum*. *Proc Natl Acad Sci U S A* **94**, 9389–93 (1997).
7. Bjorkman, J., Nagaev, I., Berg, O. G., Hughes, D. & Andersson, D. I. Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. *Science* **287**, 1479–82 (2000).
8. Mackinnon, M. J. & Marsh, K. The selection landscape of malaria parasites. *Science* **328**, 866–71 (2010).
9. Borrmann, S. *et al.* Declining responsiveness of *Plasmodium falciparum* infections to artemisinin-based combination treatments on the Kenyan coast. *PLoS ONE* **6**, e26005 (2011).
10. Sidhu, A. B. *et al.* Decreasing pfmdr1 copy number in *Plasmodium falciparum* malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. *J Infect Dis* **194**, 528–35 (2006).
11. Wongsrichanalai, C., Pickard, A. L., Wernsdorfer, W. H. & Meshnick, S. R. Epidemiology of drug-resistant malaria. *Lancet Infect Dis* **2**, 209–18 (2002).
12. Witkowski, B. *et al.* Novel phenotypic assays for the detection of artemisinin-resistant *Plasmodium falciparum* malaria in Cambodia: in-vitro and ex-vivo drug-response studies. *Lancet Infect Dis* (2013).
13. Gardner, M. J. *et al.* Genome sequence of the human malaria parasite *Plasmodium falciparum*. *Nature* **419**, 498–511 (2002).
14. van Schalkwyk, D. A. *et al.* Culture-adapted *Plasmodium falciparum* isolates from UK travellers: in vitro drug sensitivity, clonality and drug resistance markers. *Malar J* **12**, 320 (2013).
15. Hunt, P. *et al.* Experimental evolution, genetic analysis and genome re-sequencing reveal the mutation conferring artemisinin resistance in an isogenic lineage of malaria parasites. *BMC Genomics* **11**, 499 (2010).
16. Gibney, P. A., Fries, T., Bailer, S. M. & Morano, K. A. Rtr1 is the *Saccharomyces cerevisiae* homolog of a novel family of RNA polymerase II-binding proteins. *Eukaryot Cell* **7**, 938–48 (2008).
17. Price, R. N. *et al.* Mefloquine resistance in *Plasmodium falciparum* and increased pfmdr1 gene copy number. *Lancet* **364**, 438–47 (2004).
18. Yuan, J. *et al.* Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. *Science* **333**, 724–9 (2011).
19. Wootton, J. C. *et al.* Genetic diversity and chloroquine selective sweeps in *Plasmodium falciparum*. *Nature* **418**, 320–3 (2002).
20. Roper, C. *et al.* Intercontinental spread of pyrimethamine-resistant malaria. *Science* **305**, 1124 (2004).
21. Su, X. *et al.* A genetic map and recombination parameters of the human malaria parasite *Plasmodium falciparum*. *Science* **286**, 1351–3 (1999).
22. Bethke, L. L. *et al.* Duplication, gene conversion, and genetic diversity in the species-specific acyl-CoA synthetase gene family of *Plasmodium falciparum*. *Mol Biochem Parasitol* **150**, 10–24 (2006).
23. Sabeti, P. C. *et al.* Genome-wide detection and characterization of positive selection in human populations. *Nature* **449**, 913–8 (2007).
24. Mu, J. *et al.* *Plasmodium falciparum* genome-wide scans for positive selection, recombination hot spots and resistance to antimalarial drugs. *Nat Genet* **42**, 268–71 (2010).
25. Tajima, F. Statistical method for testing the neutral mutation hypothesis by DNA polymorphism. *Genetics* **123**, 585–95 (1989).
26. Amambua-Ngwa, A. *et al.* SNP genotyping identifies new signatures of selection in a deep sample of West African *Plasmodium falciparum* malaria parasites. *Mol Biol Evol* **29**, 3249–53 (2012).
27. Fidock, D. A. *et al.* Mutations in the *P. falciparum* digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. *Mol Cell* **6**, 861–71 (2000).
28. Sidhu, A. B., Verdier-Pinard, D. & Fidock, D. A. Chloroquine resistance in *Plasmodium falciparum* malaria parasites conferred by pfcr1 mutations. *Science* **298**, 210–3 (2002).
29. Hunt, P. *et al.* Gene encoding a deubiquitinating enzyme is mutated in artesunate- and chloroquine-resistant rodent malaria parasites. *Mol Microbiol* **65**, 27–40 (2007).
30. Cheeseman, I. H. *et al.* A major genome region underlying artemisinin resistance in malaria. *Science* **336**, 79–82 (2012).
31. Mok, S. *et al.* Artemisinin resistance in *Plasmodium falciparum* is associated with an altered temporal pattern of transcription. *BMC Genomics* **12**, 391 (2011).

32. Prieto, J. H., Koncarevic, S., Park, S. K., Yates, J. 3rd & Becker, K. Large-scale differential proteome analysis in *Plasmodium falciparum* under drug treatment. *PLoS ONE* **3**, e4098 (2008).
33. Dondorp, A. M. *et al.* Artemisinin resistance: current status and scenarios for containment. *Nat Rev Microbiol* **8**, 272–80.
34. Mwai, L. *et al.* Chloroquine resistance before and after its withdrawal in Kenya. *Malar J* **8**, 106 (2009).
35. Anderson, T., Nkhoma, S., Ecker, A. & Fidock, D. How can we identify parasite genes that underlie antimalarial drug resistance? *Pharmacogenomics* **12**, 59–85 (2011).
36. DeCoursey, T. E., Chandy, K. G., Gupta, S. & Cahalan, M. D. Voltage-gated K⁺ channels in human T lymphocytes: a role in mitogenesis? *Nature* **307**, 465–8 (1984).
37. Olotu, A. *et al.* Defining clinical malaria: the specificity and incidence of endpoints from active and passive surveillance of children in rural Kenya. *PLoS ONE* **5**, e15569 (2010).
38. Van Tyne, D. *et al.* Identification and functional validation of the novel antimalarial resistance locus PF10_0355 in *Plasmodium falciparum*. *PLoS Genet* **7**, e1001383 (2011).
39. Park, D. J. *et al.* Sequence-based association and selection scans identify drug resistance loci in the *Plasmodium falciparum* malaria parasite. *Proc Natl Acad Sci U S A* **109**, 13052–7 (2012).
40. Manske, M. *et al.* Analysis of *Plasmodium falciparum* diversity in natural infections by deep sequencing. *Nature* **487**, 375–9 (2012).
41. Robinson, T. *et al.* Drug-resistant genotypes and multi-clonality in *Plasmodium falciparum* analysed by direct genome sequencing from peripheral blood of malaria patients. *PLoS ONE* **6**, e23204 (2011).
42. MalariaGen. Sequence Read Archive. (Accessed on 10 Oct 2013). <http://www.malariagen.net/data/sequence-read-archive>.

Acknowledgments

We thank Ines Petersen for helpful comments and Bronwyn MacInnis for assistance. This work is published with the permission of the Director of KEMRI. This work was supported by a German Research Foundation (DFG) grant to S.B. The funding source had no role in the design of the study; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

Author contributions

S.B. and T.C. wrote the manuscript. S.B., A.N., D.K. and T.C. designed the study. S.B., J.S. and T.C. analysed the data. L.M., A.A., A.R., J.O., S.M., M.M.K., S.C. and S. Auburn generated data. P.S. and B.L. oversaw sample collection. S. Assefa, M.M. and G.M. provided data analysis tools and assisted data analysis. N.P. and K.M. coordinated the clinical study. All authors have reviewed the manuscript.

Additional information

Supplementary information accompanies this paper at <http://www.nature.com/scientificreports>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Borrmann, S. *et al.* Genome-wide screen identifies new candidate genes associated with artemisinin susceptibility in *Plasmodium falciparum* in Kenya. *Sci. Rep.* **3**, 3318; DOI:10.1038/srep03318 (2013).

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported license. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-sa/3.0>